The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam
β Scribed by Amy Matser; Anouk Urbanus; Ronald Geskus; Mirjam Kretzschmar; Maria Xiridou; Marcel Buster; Roel Coutinho; Maria Prins
- Book ID
- 108600747
- Publisher
- John Wiley and Sons
- Year
- 2012
- Tongue
- English
- Weight
- 245 KB
- Volume
- 107
- Category
- Article
- ISSN
- 0965-2140
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Quantitative estimates of the current and future burden of hepatitis C virus (HCV) disease are required to plan a public health response to the HCV epidemic with regard to both prevention and treatment. A forward projection model was used to estimate the numbers of both current and former injecting
## Abstract The distribution of HCV genotypes among injection drug users in Hong Kong was assessed in context of methadone treatment availability. Three time periods were defined by the year of initiating injectionβon or before 1980, 1981β1994, and 1995β2006βwith methadone becoming widely available
Of 74 patients who were infected with hepatitis C virus (HCV) and received interferon, 12 (16%) were positive for RNA of GB virus C (GBV-C). RNA of GBV-C was determined in sera from the co-infected patients retrospectively, and the effect of interferon on GBV-C was compared with that on HCV in them.
## Abstract The clinical relevance of occult hepatitis B virus (HBV) infection, defined as detectable HBV DNA serum/liver, in the absence of hepatitis B surface antigen (HBsAg), is unclear. We determined the prevalence of serum occult HBV infection in HIV/HCV coβinfected patients enrolled in APRICO